Richard L. Dunbar, MD Attending Physician, Cardiovascular Risk Intervention Program; Instructor of Medicine; University of Pennsylvania School of Medicine, Philadelphia
Daniel J. Rader, MD Associate Professor of Medicine, Pharmacology, and Pathology; Director, General Clinical Research Center; Associate Director, Institute for Translational Medicine and Therapeutics; University of Pennsylvania School of Medicine, Philadelphia
Address: Richard L. Dunbar, MD, PHI building, Suite 351, 39th and Market Streets; Philadelphia, PA 19104, e-mail richard.dunbar@uphs.upenn.edu
The authors’ work is supported by grants from the National Institutes of Health (T32-HL-07443-25 and KIZ-RR017625-03).
ABSTRACTBecause the landmark trials of lipid-lowering statin drugs excluded patients with very high triglyceride levels, the optimal management of hypertriglyceridemia for atherosclerosis prevention is unknown. The third report of the National Cholesterol Education Program's Adult Treatment Panel (ATP-III) provides a much-needed strategy for managing patients with high triglycerides, based on the best available evidence.
